stock
Vincerx Pharma, Inc. Common Stock
NASDAQ | VINC
0.06
USD
+0.00 (+0.00%)
AT CLOSE (AS OF May 5, 2025)
$307K
MARKET CAP
-
P/E Ratio
-15.85
EPS
$17
52 Week High
$0.045
52 Week Low
REAL ESTATE & CONSTRUCTION
Sector
VINC Chart
1D
Area
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
VINC Technicals
VINC Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$31M |
| Selling General And Administrative | $16M |
| Research And Development | $15M |
| Operating Expenses | $31M |
| Investment Income Net | - |
| Net Interest Income | $472K |
| Interest Income | $472K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$30M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | -$31M |
| Net Income | -$30M |
Revenue & Profitability
Earnings Performance
Actual: $undefined
Estimate: $undefined
Difference: $undefined
Period Qundefined
VINC Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Total Assets | $8M |
| Total Current Assets | $6.4M |
| Cash And Cash Equivalents At Carrying Value | $5M |
| Cash And Short Term Investments | $5M |
| Inventory | - |
| Current Net Receivables | $1M |
| Total Non Current Assets | $1.6M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $382K |
| Other Non Current Assets | - |
| Total Liabilities | $5.3M |
| Total Current Liabilities | $5.3M |
| Current Accounts Payable | $2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | $0 |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $3.3M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $2.7M |
| Treasury Stock | - |
| Retained Earnings | -$189M |
| Common Stock | $8K |
| Common Stock Shares Outstanding | $1.9M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$26M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.1M |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $18M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$30M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$31M |
| Selling General And Administrative | $16M |
| Research And Development | $15M |
| Operating Expenses | $31M |
| Investment Income Net | - |
| Net Interest Income | $472K |
| Interest Income | $472K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$30M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | -$31M |
| Net Income | -$30M |
VINC News
News Sentiment
The news sentiment chart shows the sentiment of news articles related to the symbol.
Vincerx Pharma, Inc. Common Stock Top Stories
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert - AZZ ( NYSE:AZZ ) , Thunder Power Holdings ( NASDAQ:AIEV ) - 21 April 2025
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - 17 April 2025
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - 17 April 2025
Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results - Bloom Energy ( NYSE:BE ) , Neogen ( NASDAQ:NEOG ) - 9 April 2025
Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earnings - Femto Technologies ( NASDAQ:FMTO ) , Delta Air Lines ( NYSE:DAL ) - 9 April 2025
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Aehr Test System ( NASDAQ:AEHR ) , Apple ( NASDAQ:AAPL ) - 9 April 2025
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - Vincerx Pharma ( NASDAQ:VINC ) - 18 March 2025
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - 18 March 2025
US Stocks Likely To Open Higher As Wall Street Watches TruTariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY ) - 3 March 2025
Why US Stock Futures Are Rising Today - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY ) - 3 March 2025
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Vincerx Pharma ( NASDAQ:VINC ) - 28 February 2025
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - 28 February 2025
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258 - Vincerx Pharma ( NASDAQ:VINC ) - 29 January 2025
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Allurion Technologies ( NYSE:ALUR ) , Aclarion ( NASDAQ:ACON ) - 27 January 2025
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders - Getty Images Holdings ( NYSE:GETY ) , Colombier Acquisition ( NYSE:CLBR ) - 10 January 2025
Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm - Getty Images Holdings ( NYSE:GETY ) , Colombier Acquisition ( NYSE:CLBR ) - 10 January 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, OMIC, NEUE, VINC on Behalf of Shareholders - Nordstrom ( NYSE:JWN ) , NeueHealth ( NYSE:NEUE ) - 3 January 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLD - 2 January 2025
Bitcoin May Exceed $250K Amid Halving And US Adoption; Taiwan Semi Expands 2-nm Chips; Boeing Drops On Crash Scrutiny - Top Headlines Today While US Slept - 30 December 2024
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Vincerx Pharma ( NASDAQ:VINC ) - 27 December 2024
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - 27 December 2024
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - 4 December 2024
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - Vincerx Pharma ( NASDAQ:VINC ) - 4 December 2024
What Makes Vincerx Pharma ( VINC ) a New Buy Stock - 10 October 2024
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates - Vincerx Pharma ( NASDAQ:VINC ) - 8 October 2024
Vincerx Pharma Reports Second Quarter 2024 Financial Results - 8 August 2024
Vincerx Pharma ( VINC ) Moves to Buy: Rationale Behind the Upgrade - 27 June 2024
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - 14 May 2024
Why Vincerx Pharma ( VINC ) Stock Is Falling - Vincerx Pharma ( NASDAQ:VINC ) - 26 April 2024
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Alphabet ( NASDAQ:GOOGL ) - 26 April 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Vincerx Pharma ( NASDAQ:VINC ) - 26 April 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - 26 April 2024
Crude Oil Down Over 1%; Cognyte Software Shares Plummet - Cognyte Software ( NASDAQ:CGNT ) , Acrivon Therapeutics ( NASDAQ:ACRV ) - 9 April 2024
Vincerx ( VINC ) Tumbles on Results From Cancer Therapy Study - 9 April 2024
Dow Dips 150 Points; Laser Photonics Shares Spike Higher - 9 April 2024
Dow Dips 150 Points; Laser Photonics Shares Spike Higher - Biophytis ( NASDAQ:BPTS ) , Acrivon Therapeutics ( NASDAQ:ACRV ) - 9 April 2024
Why Is Vincerx Pharma Stock Plummeting On Tuesday? - Vincerx Pharma ( NASDAQ:VINC ) - 9 April 2024
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings - Acrivon Therapeutics ( NASDAQ:ACRV ) , Hub Cyber Security ( NASDAQ:HUBC ) - 9 April 2024
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Biophytis ( NASDAQ:BPTS ) - 9 April 2024
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research ( AACR ) Annual Meeting 2024 - 8 April 2024
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update - 29 March 2024
Why CrowdStrike Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket - Airship AI Holdings ( NASDAQ:AISP ) , Couchbase ( NASDAQ:BASE ) - 6 March 2024
Vincerx to Present Three Posters at the American Association for Cancer Research ( AACR ) Annual Meeting 2024 - 5 March 2024
Why Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Bit Brother ( NASDAQ:BETS ) , ARB IOT Group ( NASDAQ:ARBB ) - 9 January 2024
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? - Vincerx Pharma ( NASDAQ:VINC ) - 8 January 2024
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket - Ainos ( NASDAQ:AIMD ) , Ampio Pharmaceuticals ( AMEX:AMPE ) - 8 January 2024
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma - Vincerx Pharma ( NASDAQ:VINC ) - 7 January 2024
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma - 7 January 2024
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 - 10 December 2023
Vincerx Pharma To Present Three Posters at ASH 2023 in December - 2 November 2023
VINC Profile
Vincerx Pharma, Inc. Common Stock Profile
Sector: REAL ESTATE & CONSTRUCTION
Industry: BLANK CHECKS
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company is headquartered in Palo Alto, California.
NITO 140.28%
$0.68
GNLN -5.88%
$0.0096
AGMH 21.12%
$0.0883
LGMK 2.29%
$0.0179
CNEY 16.36%
$0.165
NVNI 52.99%
$0.5145
LCID -6.72%
$2.36
NCNA 139.03%
$1.1
NVDA -0.59%
$113.82
DGLY -4.78%
$0.0319
KIDZ
33.96%
$7.18
PLTR -0.41%
$123.77
F -0.78%
$10.2
PLUG -5.74%
$0.7947
TSLA -2.42%
$280.26
SPRC 38.41%
$0.4
AAL 1.33%
$10.66
HIMS 2.76%
$41.945
AAPL -3.15%
$198.89
DNN -3.08%
$1.415
LYT -16.78%
$0.0982
MARA -9.60%
$13.09
SOFI 1.26%
$12.86
WW 22.52%
$0.7105
VHAI -11.11%
$0.0008
BTE 1.23%
$1.64
KDP 0.12%
$34.45
SNAP 1.07%
$8.54
BTG 3.40%
$3.04
WBD -1.99%
$8.37
INTC -1.70%
$20.27
AMD 1.81%
$100.59
PFE -1.36%
$23.87
PLRZ 12.87%
$1.14
AMCR -0.05%
$9.315
HOOD -1.11%
$48.05
HL 5.40%
$4.785
RIG -2.95%
$2.3
AMZN -1.91%
$186.35
RXRX -16.58%
$4.755
RGTI -8.23%
$9.7549
RIOT -5.84%
$7.9
BAC 0.10%
$41.11
APLD -2.45%
$5.17
FUBO 3.93%
$2.515
IBRX -17.32%
$2.1
ME -21.26%
$0.6063
BBD -1.88%
$2.355
AIFF 2.45%
$3.35
CUTR -10.19%
$0.0969
SMCI -4.41%
$32.2223
EJH -46.40%
$0.1079
BP 3.77%
$29.18
ABEV -1.00%
$2.465
WULF -6.85%
$2.99
PBR -3.57%
$11.195
NGD 2.47%
$3.935
BON -22.64%
$0.0499
UBER 1.35%
$85.42
GRAB -0.61%
$4.86
RIVN -2.02%
$13.55
ON -8.35%
$38.41
NIO -1.36%
$3.975
QBTS -7.84%
$7.29
KVUE -1.46%
$23.63
JBLU -1.89%
$4.67
AG 2.21%
$6.0409
T -0.31%
$27.525
LYG 1.20%
$3.795
GOOGL 0.11%
$164.21
CLSK -8.17%
$8.09
HLN 3.58%
$10.7
KGC 3.20%
$14.52
TLRY -3.45%
$0.4394
ITUB -0.89%
$6.145
XOM -2.73%
$103.31
MSFT 0.20%
$436.17
VRN -2.96%
$5.745
NOK -0.79%
$5.02
FNA 0.00%
$13.09
ACHR -6.57%
$8.68
ET -2.82%
$16.2
BERY -2.93%
$67.58
TEVA 1.27%
$16.395
DAL 2.99%
$45.52
NOVA 18.66%
$0.2137
AGNC -0.34%
$8.76
BABA 4.34%
$125.76
NCLH 0.00%
$17.37
XYZ 0.21%
$46.63
SLB -2.79%
$33.76
KMI 0.19%
$26.88
PTON 1.03%
$6.89
LYFT 4.35%
$13.2
VALE -0.59%
$9.315
GERN 1.86%
$1.4056
BRK-B -4.98%
$512.94
AES 0.79%
$10.26
PONY -6.63%
$9.71
LUMN 12.30%
$4.245
NITO 140.28%
$0.68
GNLN -5.88%
$0.0096
AGMH 21.12%
$0.0883
LGMK 2.29%
$0.0179
CNEY 16.36%
$0.165
NVNI 52.99%
$0.5145
LCID -6.72%
$2.36
NCNA 139.03%
$1.1
NVDA -0.59%
$113.82
DGLY -4.78%
$0.0319
KIDZ
33.96%
$7.18
PLTR -0.41%
$123.77
F -0.78%
$10.2
PLUG -5.74%
$0.7947
TSLA -2.42%
$280.26
SPRC 38.41%
$0.4
AAL 1.33%
$10.66
HIMS 2.76%
$41.945
AAPL -3.15%
$198.89
DNN -3.08%
$1.415
LYT -16.78%
$0.0982
MARA -9.60%
$13.09
SOFI 1.26%
$12.86
WW 22.52%
$0.7105
VHAI -11.11%
$0.0008
BTE 1.23%
$1.64
KDP 0.12%
$34.45
SNAP 1.07%
$8.54
BTG 3.40%
$3.04
WBD -1.99%
$8.37
INTC -1.70%
$20.27
AMD 1.81%
$100.59
PFE -1.36%
$23.87
PLRZ 12.87%
$1.14
AMCR -0.05%
$9.315
HOOD -1.11%
$48.05
HL 5.40%
$4.785
RIG -2.95%
$2.3
AMZN -1.91%
$186.35
RXRX -16.58%
$4.755
RGTI -8.23%
$9.7549
RIOT -5.84%
$7.9
BAC 0.10%
$41.11
APLD -2.45%
$5.17
FUBO 3.93%
$2.515
IBRX -17.32%
$2.1
ME -21.26%
$0.6063
BBD -1.88%
$2.355
AIFF 2.45%
$3.35
CUTR -10.19%
$0.0969
SMCI -4.41%
$32.2223
EJH -46.40%
$0.1079
BP 3.77%
$29.18
ABEV -1.00%
$2.465
WULF -6.85%
$2.99
PBR -3.57%
$11.195
NGD 2.47%
$3.935
BON -22.64%
$0.0499
UBER 1.35%
$85.42
GRAB -0.61%
$4.86
RIVN -2.02%
$13.55
ON -8.35%
$38.41
NIO -1.36%
$3.975
QBTS -7.84%
$7.29
KVUE -1.46%
$23.63
JBLU -1.89%
$4.67
AG 2.21%
$6.0409
T -0.31%
$27.525
LYG 1.20%
$3.795
GOOGL 0.11%
$164.21
CLSK -8.17%
$8.09
HLN 3.58%
$10.7
KGC 3.20%
$14.52
TLRY -3.45%
$0.4394
ITUB -0.89%
$6.145
XOM -2.73%
$103.31
MSFT 0.20%
$436.17
VRN -2.96%
$5.745
NOK -0.79%
$5.02
FNA 0.00%
$13.09
ACHR -6.57%
$8.68
ET -2.82%
$16.2
BERY -2.93%
$67.58
TEVA 1.27%
$16.395
DAL 2.99%
$45.52
NOVA 18.66%
$0.2137
AGNC -0.34%
$8.76
BABA 4.34%
$125.76
NCLH 0.00%
$17.37
XYZ 0.21%
$46.63
SLB -2.79%
$33.76
KMI 0.19%
$26.88
PTON 1.03%
$6.89
LYFT 4.35%
$13.2
VALE -0.59%
$9.315
GERN 1.86%
$1.4056
BRK-B -4.98%
$512.94
AES 0.79%
$10.26
PONY -6.63%
$9.71
LUMN 12.30%
$4.245
Discover more tools and features to empower your trading
Explore FeaturesQuotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.